Log in
Log in
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     
Sign up
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     
  1. Homepage
  2. Equities
  3. Switzerland
  4. Swiss Exchange
  5. BB Biotech AG
  6. Summary
    BION   CH0038389992

BB BIOTECH AG

(BION)
  Report
Delayed Swiss Exchange  -  11:31 2022-09-27 am EDT
52.50 CHF   +1.74%
09/22Bb Biotech : 22.09.2022 Rivus Pharmaceuticals Closes $132 Million Series B with participation of BB Biotech
PU
08/30Bb Biotech Ag : Moderna was just the beginning
EQ
07/22BB Biotech AG Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2022
CI
 SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisionsFunds 
Quotes 5-day view   Delayed Quote. Delayed Swiss Exchange
09/21/2022 09/22/2022 09/23/2022 09/26/2022 09/27/2022 Date
55.2(c) 53.5(c) 52.4(c) 51.6(c) 52.5(c) Last
34 446 40 240 70 607 38 385 42 607 Volume
-0.18% -3.08% -2.06% -1.53% +1.74% Change
More quotes
Estimated financial data (e)
Sales 2022 -298 M -301 M -301 M
Net income 2022 -50,3 M -50,7 M -50,7 M
Net Debt 2022 283 M 286 M 286 M
P/E ratio 2022 -8,09x
Yield 2022 7,33%
Sales 2023 500 M 504 M 504 M
Net income 2023 175 M 176 M 176 M
Net Debt 2023 276 M 279 M 279 M
P/E ratio 2023 6,63x
Yield 2023 7,70%
Capitalization 2 887 M 2 915 M 2 915 M
EV / Sales 2022 -10,6x
EV / Sales 2023 6,33x
Nbr of Employees 10
Free-Float 97,5%
More Financials
Company
BB Biotech is a portfolio company that specializes in investments in biotechnology companies. At the end of 2018, the stock portfolio, assessed at market value to be EUR3,064.2 million, breaks down by type of holding as follows: - listed companies (99.9%): primarily Ionis Pharmaceuticals (rare diseases), Gilead Sciences (infectious viral diseases and flu), Celgene Corporation (cancer and inflammation of the immune... 
Sector
Biotechnology & Medical Research
Calendar
10/21 | 01:00amEarnings Release
More about the company
Ratings of BB Biotech AG
Trading Rating :  -
Investor Rating : 
ESG Refinitiv : 
D+
More Ratings
All news about BB BIOTECH AG
09/22Bb Biotech : 22.09.2022 Rivus Pharmaceuticals Closes $132 Million Series B with participat..
PU
08/30Bb Biotech Ag : Moderna was just the beginning
EQ
07/22BB Biotech AG Reports Earnings Results for the Second Quarter and Six Months Ended June..
CI
07/22Swiss Investor BB Biotech Posts H1 Loss Amid Difficult Macroeconomic Environment
MT
07/22BB Biotech AG publishes its interim report
EQ
07/22Bb Biotech Ag : First signs of increased M&A activity due to attractive valuations
EQ
07/22Bb Biotech : Q2 Interim Report
PU
07/22Bb Biotech : Q2 Financial_Report
PU
05/24Bb Biotech Ag : Disruptive technologies are changing an entire industry
EQ
04/22BB Biotech AG Reports Earnings Results for the First Quarter Ended March 31, 2022
CI
04/22BB Biotech Swings To Q1 Loss As Total Returns Plummet
MT
04/22BB Biotech AG publishes its interim report
EQ
04/22Bb Biotech Ag : Increased investment level balanced by established core holdings
EQ
04/12Global markets live: Honda, Shopify, Meta, ASOS, Gilead Sciences...
MS
04/12BB Biotech Launches New Share Repurchase Program
MT
More news
News in other languages on BB BIOTECH AG
09/23Bb Biotech: Keller, con mRna fatto salto quantico, possibile applicazione in ..
09/19Morning Briefing - Markt Schweiz
09/16Aktien Schweiz Schluss: SMI schliesst zum Wochenschluss klar im M..
09/16Aktien Schweiz: SMI hält sich dank Schwergewichten wacker am grossen Verf..
09/16Morning Briefing - Markt Schweiz
More news
Analyst Recommendations on BB BIOTECH AG
More recommendations
ETFs positioned on BB BIOTECH AGETFs and Trackers with Trackinsight
ETF WeightVar. 5daysRatingGeography
IShares SMIM (CH) - CHF1.73%-5.20%Switzerland
UBS ETF (CH) - SMIM A-dis - CHF1.63%-5.46%Switzerland
UBS ETF (CH) - SPI Mid A-dis - CHF1.17%-5.06%Switzerland
More ETFs positioned on BB BIOTECH AG
Chart BB BIOTECH AG
Duration : Period :
BB Biotech AG Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends BB BIOTECH AG
Short TermMid-TermLong Term
TrendsBearishNeutralBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus HOLD
Number of Analysts 3
Last Close Price 52,50 CHF
Average target price 68,67 CHF
Spread / Average Target 30,8%
EPS Revisions
Managers and Directors
Michael Hutter Head-Finance & Compliance
Erich Hunziker Chairman-Supervisory Board
Daniel Koller Head-Investment Management
Clive A. Meanwell Vice Chairman-Supervisory Board
Thomas von Planta Member-Supervisory Board
Sector and Competitors
1st jan.Capi. (M$)
BB BIOTECH AG-31.95%2 915
MODERNA, INC.-51.87%46 823
IQVIA HOLDINGS INC.-35.18%34 705
LONZA GROUP AG-42.20%32 942
SEAGEN INC.-12.45%24 949
ALNYLAM PHARMACEUTICALS, INC.16.40%23 692